ensure rapid neutrophil and platelet recovery and defined the minimum requirements as 1 × 10 6 /kg, below which there is a very high risk of delayed or failed platelet Seventy-one mobilised PBSC collections were subject to CD34 ؉ cell purification using the CEPRATE SC ® stem engraftment. Either whole peripheral blood stem cells may be infused or the progenitors can first be purified. Such cell concentration system. The overall median purity of CD34 ؉ cells was 69% (6-93%). CD34 ؉ cell, and GMpurification procedures serve to 'purge' the collection of contaminating tumour cells, 13 and are a prerequisite for in CFC recoveries were 52% (8-107%) and 36% (3-118%). Purity was logarithmically related to the input vitro stem cell expansion and gene therapy. 14,15 The use of monoclonal antibodies to purify progenitors was first percentage of CD34 ؉ cells and starting requirements were established of 1% CD34 cell content for optimal described over 15 years ago, 16 with the initial studies using 'negative selection'. Subsequently, positive selection with purity and a minimum of 2 × 10 6 /kg CD34 ؉ cells to ensure recovery of our minimum engraftment threshold antibodies to the CD34 antigen was developed [17][18][19] [20] and has proved amenable to the 'scaling up' required for clinical of 1 × 10 6 /kg CD34 ؉ cells. Reduction of the washing steps reduced non-specific cell losses and shortened the practice. Several clinical scale devices are now commercially available. Important issues are the purity of the procedure but did not affect progenitor cell recovery.
Twenty-three patients with relapsed or resistant lymphoma, 27 myeloma patients and six normal donors were studied. High-dose chemo/radiotherapy with autologous stem cell All CD34 purification procedures were performed on a sinsupport has been shown to be of value in a number of gle apheresis harvest processed within 1 h of collection. In malignant disorders. [1] [2] [3] [4] [5] Peripheral blood stem cell trans-15 subjects, 2 consecutive days' apheresis collections were plantation (PBSCT) has largely replaced bone marrow processed giving a total of 71 CEPRATE (CellPro, Bothell, transplantation in the autologous setting (ABMT) because WA, USA) column procedures. The patient details and PBSCT results in a more rapid haematological recovery CD34 purification procedures performed are shown in with an attendant reduction in resource utilisation. [6] [7] [8] [9] There Table 1 . is a considerable consensus that there is a threshold requirement for peripheral blood progenitor cells assessed either Conditioning by CD34
+ enumeration or by GM-CFC. [10] [11] [12] In a study of 81 previously treated lymphoma patients all treated on the The ablative therapy used for the lymphoma patients was high-dose BEAM chemotherapy regimen, we found that the the BEAM protocol 1, 3 (BCNU 300 mg/m 2 i.v. on day 1, optimal number of CD34 + cells was у3.5 × 10 6 /kg to etoposide 200 mg/m 2 /day i.v. days 2-5, (total dose 800 mg/m 2 ) cytosine arabinoside 200 mg/m 2 twice a day on days 2-5 (total dose 1600 mg/m 2 ) and melphalan 140 PBSC mobilisation and collection cell processor (30 min). Three milligrammes (1 mg/ml) of the supplied biotinylated CD34 monoclonal antibody was PBSC were collected on a continuous flow cell separator added to the harvest for a 25-min period at room tempera-(COBE Spectra, COBE Laboratories Ltd, Gloucester, UK, ture in a final incubation volume of 75 ml. (The standard or Baxter CS3000, Baxter Healthcare Ltd, Northampton, protocol has since been revised from 3 mg antibody in 75-UK). The six normal donors were mobilised with G-CSF 150ml to 3 mg in a 150 ml volume.) The two wash steps (filgrastim) at 10 g/kg/day s.c. and apheresis collections with 1 l of PBS were repeated after the incubation period performed on day 5 and 6. Four of the lymphoma patients to remove unbound antibody (30 min). The washed CD34 were mobilised with G-CSF beginning 6 days after ESHAP antibody-labelled cells were then made up to a final volume chemotherapy (etoposide 40 mg/m 2 for 4 days, methylpredof 300 ml in PBS and connected to the CEPRATE device. nisolone 500 mg daily, cytarabine 2 g/m 2 and cisplatin 25
The column run stage of the procedure is automated and mg/m 2 over 4 days). A single vial of G-CSF (lenograstim takes 35 min. As the cells flow through the device, avidin-263 g/vial) was given daily from completion of ESHAP coated polyacrylamide beads within the immunoaffinity until harvesting was complete. Apheresis commenced from column capture the biotin moiety of the CD34-labelled cells day 15 when the recovery WBC first exceeded 3.0 × 10 9 /l. allowing the unadsorbed CD34 negative cells to run The remaining patients were mobilised with a protocol through to a 'waste' bag. The final part of the program is described previously. 6 Low-dose cyclophosphamide (1.5 mechanical agitation and rinse of the capture beads with g/m 2 ) was given on the first day (day 1) followed by G-PBS, releasing the bound CD34 + cells (adsorbed cell CSF given s.c. at 10 g/kg (filgrastim) or a single vial of fraction) into a collection bag in an approximate 90 ml vollenograstim (263 g/vial) 24 h afterwards and daily thereume. Overall the standard procedure takes 2 h. after until harvesting was complete. Two to three apheresis collections were performed on days 8 to 12 commencing when the recovery WBC first exceeded 5.0 × 10 9 /l. At least Processing modifications one unmanipulated apheresis collection was cryopreserved
In the first protocol modification (no pre-moAb wash) 3 mg and held in reserve for each patient.
of the CD34 antibody was added directly to the harvest without prior PBS washing in a final incubation volume of Purified CD34
+ cell cryopreservation between 60 ml and 110 ml and the procedure thereafter was as in the standard protocol. Omission of this pre-wash In all cases the CD34 + selection process resulted in an step reduced the processing time from around 2 h to 1. h. approximate 90 ml cell fraction which was concentrated by
In the second modification (no wash method) both the precentrifugation to 4.5 ml and an equal volume of tissue culwash and the post-antibody PBS wash steps were omitted. ture grade PBS (Dulbecco's phosphate-buffered saline Only 1 mg of the CD34 antibody was used in this protocol without calcium or magnesium; Sigma, Dorset, UK), conto prevent saturation of the avidin bead column. Following taining 15% DMSO and 8% human serum albumin added the antibody incubation step the harvest was made up to a as cryopreservative. The cells were then transferred to two final 300 ml volume in PBS containing 10 U/ml of heparin 5 ml cryopreservative vials (Nalgene, Rochester, NY, USA) and the product loaded on the column. CD34 + selected cells and left at −80°C overnight in a controlled rate freezing were obtained from the apheresis product within 1 h with device (Nalgene, Cryo 1°C freezing container). The followthis protocol. ing day the vials were quickly transferred to sterile 15-ml polypropylene tubes (Becton Dickinson, Franklin Lakes, NY, USA), secured in a cardboard folder and stored in Progenitor evaluation liquid nitrogen.
In all cases samples were removed for white cell and progenitor counts from the harvest product, the antibody-labStem cell purification elled harvest as loaded on the column and from unadsorbed and adsorbed (CD34 + cell purified) fractions. CD34 + cells Using the standard CEPRATE protocol the apheresis product was washed twice with 1 l of tissue culture grade phoswere measured by flow cytometry as described previously 21 with matched irrelevant control or directly conjugated phate-buffered saline (PBS; Sigma) using a COBE 2991 CD34-phycoerythrin monoclonal antibody (HPCA-2PE; viously defined as the minimum target to ensure prompt haematological engraftment.
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Becton Dickinson). Cytocentrifuge preparations were prepared from the CD34 + cell-purified fraction in each proMost notably there was a wide range of purities and yields obtained. This in part reflects the variable cellular cedure and stained with May-Grünwald Giemsa for blast cell morphology as a rapid guide to column performance. A input from different harvests. A logarithmic relationship was observed between harvest CD34 concentration and second cytospin was stained for CD34
+ cells using alkaline phosphatase-anti-alkaline phosphatase (APAAP) immunoresultant purity in the CD34 enriched fraction ( Figure 1 ). In those patients in whom the percentage of CD34 + cells enzymatic staining as previously described. 6 Granulocyte-monocyte colony-forming cells (GM-CFC) in the PBSC collection was Ͼ1% (n = 17) the median CD34 + cell dose prior to processing was 1.9 × 10 6 /kg and and burst-forming units erythroid (BFU-E) were simultaneously evaluated in a methylcellulose based clonogenic the purity of the CD34 + cell fraction was 46% with a median dose in the final fraction of 0.8 × 10 6 /kg. Only 6/17 assay medium as previously described. 12 Harvest PBSC cells were plated in triplicate at concentrations of (35%) of final fractions contained the minimum requirement of 1 × 10 6 /kg ( Table 2 ). In the remaining 54 individ-2.5 × 10 4 /ml, the CD34 unadsorbed cell fraction at 1 × 10 5 /ml and purified CD34 + cells at 1 × 10 3 /ml and uals with Ͼ1% CD34 + cells in the PBSC collection the median input dose was 4.6 × 10 6 /kg and the final CD34 + 2.5 × 10 2 /ml. Colonies were counted after 14 days incubation at 37°C in a humidified CO 2 atmosphere.
cell purity was 76% with a median dose in the final fraction of 2.8 × 10 6 /kg. Fifty-two out of 54 (96%) of procedures resulted in a final yield of Ͼ1 × 10 6 /kg CD34 + cells.
Calculations used
Analysis of the CD34 + cells input in absolute cell numbers gives similar data. Of those 12 individuals in whom The following calculations were made for progenitor recovery (yields) and overall WBC losses.
the starting material contained Ͻ2 × 10 6 /kg only 4/12 procedures resulted in an adequate number of CD34 + cells in the final fraction. In those patients with Ͼ2 × 10 6 /kg CD34 + CD34 recovery % = Harvest CD34 + × 10 6 Purified CD34 + cells × 10 6 × 100 cells in the starting material this was 54/59 (92%).
GM-CFC recovery % =
Harvest GM-CFC × 10 5 GM-CFC in purified CD34 + cells × 10 5 × 100
Assessment of yield variability
Overall WBC losses % = 100 − Harvest WBC × 10 9 WBC recovered from column × 10 9 × 100 Although cell purity was closely related to CD34 + cell input, the CD34 + cell yield was highly variable (Figure 2 ) and unpredictable. To assess whether this was due to techResults nical variation or was patient-specific, nine patients had PBSC purified and processed identically on consecutive Progenitor cell purity and recovery (yields) days. Input cell numbers were similar on each day for the paired harvests, the median starting dose and percentage of Seventy-one CD34 selection procedures were performed on CD34 + cells was 5.0 × 10 6 /kg and 1.3% and 4.1 × 10 6 /kg 56 subjects. Overall the median purity of the CD34 + cell and 1.2%. There was again marked inter-individual variaenriched fraction was 69% with 52% recovery of the startbility but the yields on the 2 days in individual patients ing harvest CD34 + cells ( Table 2 ). The losses of CD34 + were similar (Figure 3 ). cells were comparable to the overall white cell losses which were approximately 50% if the standard processing protocol procedure was employed. The recovery of GM-CFC Effects of the pre-column washing steps overall was slighty less than for CD34 + cells at 36%. The CD34 + cells obtained correlated with the input CD34 + cell There were considerable non-specific cell losses associated with the recommended full procedure and in an effort to number (r = 0.796) and the median yield from a single column procedure was 1.9 × 10 6 /kg. In 51/71 instances reduce these, and thus hopefully improve the final CD34 + cell yield, modifications were made to remove one or both (82%) Ͼ1 × 10 6 /kg were obtained which we have pre- of the preparative washing steps. The standard protocol was performed in 21 patients and included washing the harvest cells twice in 1 l PBS before addition of the CD34 antibody followed by a second PBS wash after the incubation period.
To reduce non-specific cell loss during centrifugation, the antibody was added direct to the apheresis product in 20 cases. This resulted in a reduction in total cell losses from 50 to 34%. To further minimise non-specific WBC losses a final cohort of 30 apheresis products was processed without any pre-column wash steps (no-wash method). Nonspecific white cell losses were reduced further but the purity and yield of CD34 + cells were similar with all three processing methods (Table 3 ). The protocol modifications although not improving CD34 + cell yield did result in a worthwhile time saving from 2 h of 1 h.
To futher ensure that these modifications were not deleterious to the purified CD34 + cell yield two consecutive apheresis collections were processed in a further six starting dose of CD34 + cells was similar on both days as was the percentage of CD34 + cells in the starting material, recovery was rapid at 12 and 13 days for neutrophil and platelet recovery, respectively. the median values being 3.3 × 10 6 /kg and 1.3% in the collections subjected to the PBS wash procedure and 4.0 × 10 6 /kg and 1.6% in the collections with the no-wash Discussion method. The total cell losses were significantly reduced from 48% with the PBS wash procedure and 11% with the This large experience with the CEPRATE purification device confirms that it is reliable and easy to use in the no-wash method (P = 0.0003). As with the larger cohort however the final CD34
+ cell yield and purity were similar, clinical setting. The overall CD34 + cell purity and yield in all 71 CEPRATE procedures of 69 and 52% compares with being 1.8 × 10 6 /kg and 66% respectively with the PBS wash products and 1.9 × 10 6 /kg and 67% respectively with PBS values of 42 and 52% reported by Shpall et al 22 /kg, cells and to allow for the losses associated with purification at least 2 × 10 6 /kg CD34 + cells are required prior to purifiSeven of the 50 lymphoma and myeloma patients have not yet had their purified CD34
+ cells returned, one patient died cation. In a series of 97 pre-treated lymphoma patients mobilised with cyclophosphamide and G-CSF 12 only 51 of disease progression and a further patient died at day +2 of BEAM chemotherapy and is not evaluable.
patients (53%) achieved this target with a single apheresis. This means that if CD34 + cell purification is to have wider Thirty-seven have had their purified CD34
+ cells returned alone after BEAM chemotherapy (n = 17) or meluse two or more purification procedures must be performed on consecutive apheresis collections or the collections phalan/TBI (n = 20). The median time to recovery of neutrophils of 0.5 × 10 9 /l was 12 days (range 9-23 days) with pooled and processed on the same column. In the 97 patients referred to above, pooling of two collections only two patients having slow recovery defined as greater than 21 days. Seventeen patients received G-CSF from 6 allowed achievement of the 2 × 10 6 /kg CD34 + cell threshold in an additional 20 patients (21%). Twenty-six percent days after the infusion of purified CD34 + cells and the median time to neutrophil recovery in these patients was of patients still remain below this threshold, although it is likely that this number would be less if patient progenitor 12 days (range 10-22 days) compared to 14.5 days (range 11-23 days) in the remainder (P = 0.05). The median time cells were mobilised and collected at an earlier stage of the disease. The use of two or more CD34 selections per patient to attainment of platelet independence, defined as a sustained, unsupported platelet count above 15 × 10 9 /l without raises financial constraints, encouraging most centres to pool collections. Some users have reported poor cell bleeding, was 13 days (range 7-100) with G-CSF administration having no effect. Three patients had slow platelet recoveries associated with the processing of stored PBSC products however, and a study is in progress to determine recovery (22, 26 and 27 days) and four patients had delayed recovery at 32, 36, 41 and 100 days. The incidence of optimal storage conditions. A noteworthy finding was that the purity of the final fracdelayed platelet recovery 4/37 (11%) is the same as we have published previously (8%) in a series of 75 lymphoma tion achieved was closely related to the input CD34 + cell percentage. A starting percentage of у1% was found to be patients who received unmanipulated PBSC. 12 The four patients with delayed platelet recovery after infusion of associated with a high probability that the final purity would be Ͼ60% (44/54 cases). The percentage of CD34 + CD34 + cell-purified PBSC received 3.1, 1.1, 1.6 and 0.9 × 10 6 /kg CD34 cells which was in each case below our cells in the starting collection is of course related to the absolute number of CD34 + cells in the harvest and in genpreviously defined optimal threshold of 3.5 × 10 6 /kg.
12 The one case that took 100 days to become platelet-independent eral a 1% threshold relates to an absolute threshold of about 2 × 10 6 /kg which is required from the viewpoint of 50% received less than our 'minimal' threshold number of 1 × 10 6 /kg CD34 + cells. losses. In practice therefore it is possible to abort a CD34 + cell purification before cell losses and unnecessary expense In the final four patients the purified CD34 + cell dose was considered inadequate to return alone at 0.6, 0.3, 0.3 have been incurred. Appreciation of the relationship between 'input' and 'output' will also be important when and 0.01 × 10 6 /kg and in each case two unmanipulated back-up PBSC collections were returned concomitantly. In comparing the performance of different purification devices. From a clinical standpoint 'input' cells must refer three patients even the pooled total dose of CD34 + cells collected remained low at 0.8, 0.6 and 0.3 × 10 6 /kg and a to harvest collection values. A statement of final purity and yield without input CD34 + percentages is not meaningful. bone marrow harvest was collected in the poorest mobiliser. Slow neutrophil recovery was seen in two of these patients
In this study, we have evaluated the impact of reducing the centrifugation/wash steps to try and minimise the cell at 26, 24 and 12 days and delayed platelet recovery in two at 18, 59 and 80 days, respectively. In the fourth patient losses. The non-specific losses can be significantly ameliorated by such modifications but unfortunately the specific the two pooled back up PBSC collections were above the minimum threshold level at 2.8 × 10 6 /kg CD34 + cells and CD34 + cell losses are not reduced. 
